Asthenozoospermia is a decrease in sperm motility. According to the World Health Organization (WHO), a progressive motility of more than 32% (31-34%) is considered normal, while total motility (progressive + non-progressive) is 40% (38-42%).
When in two seminograms performed on a patient with a period of 2-3 months between one and the other a lower motility is found, it is considered asthenozoospermia.
The first line of treatment should be aimed at improving habits and quality of life: not smoking, not drinking alcohol, not taking drugs, exercising, not being overweight, eating a balanced diet, etc.
As for the possible pharmacological treatment, it should always be indicated by a urologist. Androgens, human menopausal hCG/gonadotropin, bromocriptine, alpha-blockers, systemic corticosteroids and magnesium supplements have been shown not to be effective in the treatment of asthenozoospermia. In addition, follicle-stimulating hormone and anti-estrogens in combination with testosterone may be beneficial treatments in selected patients (always under strict medical supervision by a specialist).
The treatment of infertility caused by such asthenozoospermia is the use of assisted reproduction techniques that facilitate the arrival or entry of sperm into the oocyte (egg), such as artificial insemination or in vitro fertilization with or without ICSI.